1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Institut d'Oncologia – VHIO
  4. Articles científics - VHIO
  5. View Item

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

To access the full text documents, please follow this link: http://hdl.handle.net/11351/6429

Author

Lanza, Carlo

Romano, Marco

Cortés Castan, Javier

de las Heras, Begoña

Saini, Kamal S.

de Azambuja, Evandro

Other authors

Institut Català de la Salut

[Saini KS] Covance Inc, Princeton, NJ, USA. East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK. [Lanza C, Romano M] Covance Inc, Princeton, NJ, USA. [de Azambuja E] Institut Jules Bordet, Brussels, Belgium. Université Libre de Bruxelles (U.L.B), Brussels, Belgium. [Cortes J] IOB Institute of Oncology, Quiron Group, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medica Scientia Innovation Research, Ridgewood, NJ, USA. [de Las Heras B] Covance Inc, Princeton, NJ, USA. Madrid Medical Doctors Association, Madrid, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-10-21T09:29:58Z

2021-10-21T09:29:58Z

2020-09



Share

Abstract

Desenvolupament de fàrmacs; Infecció viral

Desarrollo de fármacos; Infección viral

Drug development; Viral infection

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Document Type

Article

Published version

Language

English

Subjects and keywords

COVID-19 (Malaltia); Medicaments antineoplàstics - Ús terapèutic; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; Other subheadings::Other subheadings::/therapeutic use; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Repositioning; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos; Otros calificadores::Otros calificadores::/uso terapéutico; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::nuevas indicaciones de medicamentos

Publisher

Springer Nature

Related items

British Journal of Cancer;123

https://doi.org/10.1038/s41416-020-0948-x

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)

Articles científics - VHIO [468]